SLCO1B1 and Myalgia: Patients with SLCO1B1 decreased or poor function phenotype (c.521 T > C) had increased risk in developing myalgia with atorvastatin (P  =  3.35×10-3, OR = 1.27, 95% CI = 1.08–1.48) and severe SAM with simvastatin (P  =  3.14×10-3, OR = 2.91, 95% CI = 1.43–5.91) (Fig. 5d, e and Supplementary Table 9).